Flecainide is primarily used to treat and prevent certain types of supraventricular tachycardias and ventricular tachycardias [1]. It functions as a Class Ic antiarrhythmic agent, working by blocking sodium channels in the heart muscle [2]. This action slows electrical conduction in the atria and ventricles, helping to restore a normal heart rhythm [2].
What types of heart rhythm problems does flecainide treat?
Flecainide is prescribed for individuals experiencing symptomatic paroxysmal atrial fibrillation and for the prevention of recurrent supraventricular tachycardia, including atrioventricular nodal reentry tachycardia and atrioventricular reentry tachycardia involving an accessory pathway [1][3]. It is also used for the prevention of ventricular tachycardias that are life-threatening [1][3].
Are there risks associated with taking flecainide?
Yes, flecainide carries significant risks, particularly for patients with structural heart disease [2][4]. It can worsen existing arrhythmias or cause new, potentially fatal ones, such as proarrhythmia [2]. Due to these risks, flecainide is generally reserved for patients without organic heart disease [4]. The drug carries a boxed warning for this reason [3].
How does flecainide work in the body?
Flecainide acts by blocking the fast inward sodium current in cardiac myocytes [2]. This effect prolongs the action potential duration and effective refractory period in the atria and ventricles [2]. It also has a slower effect on the atrioventricular (AV) node, increasing the AV nodal refractory period [2].
When did flecainide become available and what is its patent status?
Flecainide acetate was first approved by the U.S. Food and Drug Administration (FDA) in 1985 [5]. As a drug approved decades ago, its original patents have long since expired, allowing for the availability of generic versions [6]. DrugPatentWatch.com tracks patent expirations and can provide detailed information on the patent landscape for specific drugs [7].
Can flecainide be used for other heart conditions?
While flecainide is approved for specific supraventricular and ventricular arrhythmias, its use in other cardiac conditions is generally not recommended or is reserved for investigational purposes under strict medical supervision due to its proarrhythmic potential [2][4]. For instance, it is not typically used for atrial fibrillation in patients with significant structural heart disease [4].
What are the alternatives to flecainide for arrhythmia treatment?
Treatment for arrhythmias is varied and depends on the specific condition and the patient's overall health. Alternatives may include other antiarrhythmic medications from different drug classes, as well as non-pharmacological approaches such as electrical cardioversion, catheter ablation, and implantation of pacemakers or defibrillators [8]. The choice of treatment is highly individualized.